NCT01345188

Ranolazine in Ischemic Cardiomyopathy

Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Midwest Cardiovascular Research Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.

Conditions

• Cardiomyopathy
• Chest Pain
• Dyspnea

Interventions

Type	Name	Description
DRUG	Ranexa	1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
DRUG	Placebo	1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Timeline

• Start date: 2011-04-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2011-04-29
• Last updated: 2024-12-09
• Results posted: 2018-09-06

Locations

1 site across 1 country: United States